If PH-ILD studies translate into the real world, the market opportunity for Liquidia is enormous. Where should we expect LQDA stock to be in the next few months? Find out.
United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...
UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...
Arquitos returned 29.6% net of fees and expenses in 2024, compared to 25.0% for the S&P 500. Click here to read the full ...
United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...
Zacks.com on MSN7d
Merck Halts Second PAH Drug Study Early on Strong Efficacy ResultsMerck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions involving the company's common stock. On January 21, Benkowitz sold ...
“At this year’s annual congress, we are delighted to share further findings that support long-term outcomes and dosing of Tyvaso DPI, as well as interim data from our PHINDER study that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback